Caused by:
Results in hypopituitarism, rare visual defects, CSF in sella turcica
Secondary Empty Sella Syndrome
Clinical manifestations d/t direct or associated hormone effects
Women:
Men:
Hyperprolactinemia
Medical therapy for acromegaly
Cabergoline - dopamine agonist
Octreotide, lanreotide - somatostatin analogs
Pegvisomant - GH Receptor antagonist
Resistance to ADH
Caused by:
Nephrogenic Diabetes Insipidus
Over 90% in women Associated w/ multiple hormonal abnormalities:
Hormonal abnormalities reversible w/ weight gain
Anorexia nervosa
Dopamine agonists used to treat hyperprolactinemia
Efficacious in normalizing prolactin levels
Efficacious in shrinking tumors
Cannot nurse while on these medications d/t suppressed prolactin
Cabergoline and bromocriptine
Manifestations:
Diagnosis:
Common:
Treatment:
Gonadotrophin deficiency
Associated w/ failure of postpartum lactation
Usually associated with loss of other hormones
NO treatment
Hypoprolactinemia
Clinical characteristics:
Normal past history of gonadal function
Enormous pituitary size causing mass effects
Can make isolated alpha and beta subunits or intact LH or intact FSH
Gonadotroph adenomas
HA Visual field defects
Cranial nerve palsies
Hypopituitarism
Diabetes Insipidus
Temp dysregulation and dysregulation of food intake (rare)
Mass effects of sellar lesions
Congenital malformations
Hydrocephalus Tumors
Inflammation/infection
Etiology of Hypothalamic Dysfunction
Manifestation:
secondary hypoadrenalism
Inability to respond to stress
Diagnosis:
ACTH deficiency
Inability to suppress GH levels during an oral glucose tolerance test
Elevated serum IGF-1 levels MRI to identify location, size of tumor
Visual fields if tumor found to be abutting chiasm
Evaluate for hypopituitarism if macroadenoma
Diagnostic testing for acromegaly
Normally caused by a pituitary tumor
Increased fat mass
Decreased muscle mass
Decreased energy, increased fatigue
Poor QOL
Adult GH deficiency
Medical therapies for Cushing’s
Steroidogenesis blockers
Steroid receptor antagonist
GH receptor antagonist used to treat acromegaly
Less activation –> less IGF-1 production
Pegvisomant
Deficiency of vasopressin secretion or action
Polyuria - large volume of dilute urine
Polydipsia - increased thirst
Diabetes Insipidus
Hypopituitarism
Disordered vasopressin regulation
Hyperprolactinemia
Other hypothalamic dysfunction if very large and bilateral
Manifestations of hypothalamic disease
Mutation in Type 1A subunit of Protein Kinase A (PRKAR1A)
Pituitary adenoma in 10% (GH producing)
Spotty skin pigmentation
Myxomas
Schwannomas
Pigmented nodular adrenal cortical disease causing Cushing’s syndrome in 30%
Carney Complex
Mutations in HESX1, SOX2, SOX3, OTX2
Absent septum pellucidum
Agenesis of corpus callosum
Optic nerve dysplasia
Hypothalamic developemental dysfunction leads to hypopituitarism
Variable presentation
Septo-Optic Dysplasia
Pituitary transcription factor mutation of __ GH, TSH, PRL deficiencies
Pit-1
Infiltrative hypothalamic disease
May be pulmonary interstitial disease
Osteolytic lesions, especially in jaw
Treat w/ alkylating agents, focal irradiation, vinca alkaloids
Langerhans Cell Histiocytosis
Asymptomatic Symptomatic d/t mass effects
Primary therapy is surgery
Nonfunctional pituitary adenomas
Prolactinomas
Clinically nonfunctional adenomas
Indications for radiotherapy